Back to bills
Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026
Last updated: 6/17/2026 · Introduced: 4/30/2026
Author: Lisa Murkowski (R-AK)
TL;DR (AI)
- This bill extends the Accelerating Access to Critical Therapies for ALS Act through fiscal year 2031.
- It requires the Secretary to consider clinical trial status and enrollment data when reviewing grant renewal applications for investigational ALS drugs and allows for requests of interim clinical trial data.
- The bill mandates a report from the FDA within one year of enactment, evaluating and updating the action plan for ALS and other rare neurodegenerative diseases.
Verified Votes
No verified votes yet.
Community Votes
No community votes yet. Be the first!
Voting as guest · Sign in for verified votes
Other Sections
Includes provisions on preamble, short title., and 4 more.
6 sections
Click "Show details" to explore individual sections. Use the community vote above or visit All Sections to vote per section.
Want the full experience?
Create a free account to cast verified votes on each section, get a personalized summary, and track your voting history.
Create Free Account